Drug Trial Radar · NCT06767761
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin
Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
580
Planned (sponsor's estimate)
Start
Feb 18, 2025
Primary completion
Mar 19, 2026
Study completion Apr 9, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 in Combination with Insulin Aspart (with or without Non-Insulin Antidiabetic Agents) in Subjects with Type 2 Diabetes Mellitus (T2DM) Treated with Basal+Prandial Insulin Treatment
Conditions
- Diabetes
Interventions
GZR4Drug
GZR4 s.c., once-weekly,treat-to-target dose
Insulin Glargine U100 groupDrug
Insulin Glargine U100 s.c.,once-daily,treat-to-target dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: From baseline (week 0) to week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second XIANGYA Hospital Of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.